Managing trend amid a global pandemic

In the face of the COVID-19 crisis, we worked together with clients to solve urgent and emerging needs with innovation, agility and focus while delivering results. See a snapshot of what we were able to help our clients achieve.
DTR 3
Held unit cost increases to 0.9%
For the fourth year in a row, we limited the increase in drug unit costs to under 1%, despite an average increase of 4.3% in list prices for brand drugs, by leveraging therapeutic mix and supply chain.
DTR 1
Delivered $45 million in savings
Leveraging innovative clinical programs and leveraging data to inform key decisions, we realized significant savings for our clients in 2020.
DTR 2
Getting ahead of the growth in specialty
For the first time, spending on specialty drugs accounted for more than half of total drug spend (51%). Our solutions and capabilities helped our clients stay ahead of this growth.
DTR 4
Negative trend for 1/3 of our commercial clients plans
Even in 2020, one trend held. For plans that took advantage of opportunities to help patients use the right drug—in the right amount and from the right pharmacy—the result was lower spending.